As DEVARGE,

Our objectives are to be the pioneer in generic drug development, to make a difference by developing value-added products, to develop products for regulated markets and have these products authorized and launched in these markets, to invest in the future by adapting new technologies to our company, to develop products with high added value through university-industry cooperation, and to ensure that the rights of our company are protected via patent registration.

We work to be the top generic drug manufacturer in Türkiye and to develop high added value products exportable to international markets.

With our strong staff consisting of 504 trained personnel, who are experts in their fields, as well as laboratories and manufacturing sites equipped with cutting-edge technology, we work to develop innovative products.

We strive to perform R&D activities in compliance with all ethical and legal principles, in a manner that meets the expectations of the concerned authorities; to prove that the safety, efficacy, and quality of the products do not change throughout their shelf life, to increase product accessibility, to develop sustainable methods to enhance efficiency, and to adapt production to new technologies.

The operating principle requires product quality that meets current standards, and focuses on finding new formulations, new dosage forms, and different routes of synthesis and/or new polymorph methods that do not infringe patents for raw materials.

Our long-term goal is to continue being a pioneer in developing generic drugs, to ensure vertical integration in strategic products, to compete globally in developing active ingredients and new polymorphs, to create differentiation by developing valueadded products, to continue developing products for regulated markets (EMA and FDA), to increase our competence by adapting new technologies, to develop high added value products through university-industry collaboration, and to protect our innovative intellectual property with patent registration.

DEVARGE comprises Pharmaceutical Development, Analytical Development, Manufacturing Excellence, API Development, CMC Documentation, Patent, and Biotechnology units.

DEVARGE contains Pre-formulation and pilot manufacturing areas, synthesis and scale-up laboratories, stability areas, analytical development laboratories, and biotechnology laboratories.

In 2024;

• Alternative sourcing studies were conducted for active and excipient materials to reduce costs and prevent potential supply chain issues, covering a total of 57 commercial products, including 31 active pharmaceutical ingredients (APIs).
• Process improvement activities were carried out to enhance the efficiency of 15 commercial products.
• The production of 5 dietary supplement products was successfully completed.
• 7 patent applications were filed, and one patent was successfully registered in Türkiye.

Pharmaceutical Technology

Products in all dosage forms (solids, semi-solids, liquids, inhalation, sterile, oncolytic, capsule, SVP, LVP) are developed at laboratories equipped with the state-of-the-art technology. The Pharmaceutical Technology subdivision comprises the following R&D areas:

• Pre-formulation laboratory

• High-potency laboratory

• Pilot manufacturing

• Analytical development laboratories (instrumental analysis, Wet Chemistry, Inhalation and Oncolytic)

• Stability cabinets

API

DEVA became the first company in Turkey to manufacture an active pharmaceutical ingredient by undertaking tetracycline and oxytetracycline manufacturing operations in 1970, and has since grown its investments in this field, becoming a pioneer in API manufacturing.

In 1981, DEVA began manufacturing gentamicin, becoming one of the five companies in the world able to manufacture this active substance.

DEVA API R&D subdivision is able to perform multi-layered and complex chemical synthesis, based on complexity of the API compound, leveraging its state-of-the-art equipment and staff of experienced professionals. The API subdivision operates within the R&D center that was established in 2009, successfully conducting projects and expanding the product portfolio for both domestic and international markets.

Biotechnology

DEVA undertakes biotechnological manufacturing operations, including biosimilar research and development, to high quality standards and in line with the requirements of pharmaceutical authorities.

The biotechnology operation is conducted using collaborations with universities and TÜBİTAK project assistances, at well-equipped development laboratories with clinical and pre-clinical support. DEVA continues advancing its aspirations with a growing biotechnology team of young and dynamic scientists focusing on research and development.